Skip to main content

Table 4 Univariate and multivariate Cox models of DFS

From: Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

 

Univariate analysis

Multivariate analysis

HR

95% CI

P value

HR

95% CI

P value

Age

1.034

0.998–1.070

0.061

1.036

0.850–2.637

0.043

BMI

0.989

0.930–1.053

0.739

   

HR status

1.698

0.868–3.323

0.122

1.799

0.916–3.536

0.088

Menopausal status

1.393

0.795–2.442

0.247

   

cN status

2.724

1.420–5.224

0.003

2.811

1.461–5.407

0.002

cT status

1.569

0.896–2.748

0.115

1.497

0.850–2.637

0.162

Zoledronic acid

0.656

0.371–1.160

0.147

   
  1. Bold values indicate that P < 0.05
  2. DFS disease-free survival, HR hazard ratio, CI confidence interval, BMI body mass index
  3. the italicized data have a significance of > 0.05